Enbrel To Cut Into Remicade’s Medicare Monopoly Via Part D, Amgen Says
Executive Summary
Amgen sees the advent of Part D as an opportunity for Enbrel to capture some of the Medicare TNF inhibitor rheumatoid arthritis market share currently held byJohnson & Johnson's Remicade